Our new analysis is now available open access in Therapeutic Innovation & Regulatory Science: Optimizing Biomedical Health Efficiency: Unlocking the Full Potential of Life Science Innovation Through System DesignAuthors Gigi … Read More
Journal of Managed Care + Specialty Pharmacy: 10-year projection of pediatric onset rare disease therapy approvals, treated patients, and list price revenues
New research in Journal of Managed Care + Specialty Pharmacy (JMCP) provides insights into the future landscape of treatments for rare diseases that present in childhood, offering a balanced picture … Read More
Nature Reviews Drug Discovery: Clinical development success rates for durable cell and gene therapies
Our article compares the clinical development success rates of durable cell and gene therapies (dCGTs) from 1988 to 2023 with BIO and IQVIA’s published benchmarks for all therapeutic modalities. As … Read More
Health Affairs Forefront: Bringing Systems Thinking to Drug Value Assessment
Drug value assessments generally fail to account for the complexities of health care systems and thus can misinform price negotiations and lead to overly restrictive access policies. Our [new article … Read More
BioCentury OpEd: Biomedical Innovation Requires Health System Innovation
New guest commentary in BioCentury by Gigi Hirsch & Jane Barlow seeds a series of discussions now underway to shape priorities for the “Next Big Thing” in the Center for … Read More
BioCentury OpEd: Biomedical Innovation Requires Health System Innovation
New guest commentary in BioCentury by Gigi Hirsch & Jane Barlow seeds a series of discussions now underway to shape priorities for the “Next Big Thing” in the Center for … Read More
Better Outcomes Tracking: A First Step In Improving Access To New Treatments
New article in Health Affairs Forefront Transformative new pharmaceutical treatments hold the promise of changing patients’ lives by slowing and curing disease, improving well-being, and advancing quality of life. Yet, … Read More
Payer Perspectives on Gene Therapy Reimbursement
J.F. Barlow; M.W. Courtney; M. Trusheim. Pharmaceutical Executive, 04/2020 The reimbursement of emerging durable and potentially curative cell and gene therapies challenge US payers due to their high upfront costs. … Read More
Payer Perspectives on Reimbursement of One-Time High-Cost Durable Therapies
Pharmaceutical Executive, January 9, 2020Matt W. Courtney, Jane F. Barlow, Mark Trusheim The reimbursement of emerging durable and potentially curative cell and gene therapies challenge U.S. payers due to their … Read More
Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System
Value in Health, June 2019Casey Quinn, Colin Young, Jonathan Thomas, and Mark Trusheim Cell and gene therapies promise durable clinical benefit from a single treatment course. High upfront reimbursement for … Read More